The Botanix Pharmaceuticals Ltd (ASX: BOT) share price has been placed in a trading halt today. This comes after the management team asked the ASX to pause trading while it prepares an announcement.
Before the halt, Botanix shares were down 2.61% to 11 cents. The stock is now down about 17% so far this year, adding to what has already been a tough period for investors.
According to the ASX notice, trading will remain on hold until the company makes its announcement or until normal trading resumes on Tuesday, 17 February 2026, whichever comes first.
Why has trading been halted?
In its announcement, Botanix said the trading halt relates to a potential capital raising.
A capital raising involves issuing new shares to existing and sometimes new investors to raise funds. The proceeds are then used to grow the business, strengthen the balance sheet, or support product launches.
The company has not yet disclosed the size, structure, or pricing of the proposed raising. Further details are expected once trading resumes.
A quick refresher on Botanix
Botanix is a dermatology company based in the United States.
Its lead product, Sofdra, has received US Food and Drug Administration (FDA) approval for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating.
Sofdra is described as the first and only new chemical treatment approved for this condition, marking an important milestone for the company.
As Botanix builds out its commercial operations, it is not yet consistently profitable. The business requires funding to support marketing, distribution, and day-to-day operations as it rolls out Sofdra.
The company has a market capitalisation of about $220 million and nearly 2 billion shares on issue.
What investors should watch next
When trading resumes, the market reaction will likely depend on the size and pricing of the capital raising.
If new shares are issued at a discount to the last traded price of 11 cents, it could put short-term pressure on the share price. On the other hand, if investors see the raising as strengthening the company’s position, sentiment could improve.
Investors will also want clarity on how the funds will be used and whether new shareholders will have a chance to participate.
Foolish Takeaway
While capital raisings can strengthen a company’s position, they can also dilute the existing value of current shareholdings.
Ultimately, Botanix’s longer-term performance will hinge on whether Sofdra can generate impactful sales and move the business toward profitability.
The post This ASX biotech just entered a trading halt. Here’s what we know appeared first on The Motley Fool Australia.
Should you invest $1,000 in Botanix Pharmaceuticals Limited right now?
Before you buy Botanix Pharmaceuticals Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Botanix Pharmaceuticals Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 Jan 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Why Austal, Cochlear, Nick Scali, and WiseTech shares are tumbling today
- 13 ASX 200 shares hit multi-year lows as the market takes a breather
- ASX beginner? Here’s what I would do if I were starting with $500
- Everything you need to know about the latest Cochlear dividend
- ASX shares with ex-dividend dates next week
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.